← FDA DRUG APPROVALS

FDA ANDA · ANDA211624

FOSAPREPITANT DIMEGLUMINE

Sponsor: GENEYORK PHARMS

APPLICATION
ANDA211624
TYPE
ANDA
ORIGINAL APPROVAL
2019-09-05
LATEST ACTION
2021-01-06
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Discontinued

Products

FOSAPREPITANT DIMEGLUMINEDiscontinued
FOSAPREPITANT DIMEGLUMINE EQ 150MG BASE/VIAL · POWDER · INTRAVENOUS

Approval history

2021-01-06Labeling · Supplement 1 · standardAP
2019-09-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →